GB Sciences are looking for international suppliers that produce minor cannabinoids and terpenes to ensure that it can expand testing beyond their planned, initial Phase 0 Trial.
To date, approximately 20 testing labs have received temporary business licenses in California which many experts believe is nowhere near enough to meet future demand.
Medical cannabis and marijuana extracts should not be used for the treatment of obstructive sleep apnea, according to a statement from the American Academy of Sleep Medicine.
The company behind the study hopes to complete their study evaluating the use of cannabis oil for treating chronic pain by fall 2018.
The launch of Delta™ means producers are now able to to recreate and restore the full plant terpene profile in any oil-based cannabis product.
The trial will help distinguish between multiple formulations based on various measures, including pharmacological and pharmacodynamic measures that may be predictive of drug efficacy.